Sökning: WFRF:(Glotz Denis)
> (2019) >
Safety and efficacy...
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies
-
- Glotz, Denis (författare)
- INSERM, Paris Translat Res Ctr Organ Transplantat, Unite Mixte Rech S970, Paris, France;St Louis Hosp, AP HP, INSERM, Dept Nephrol & Organ Transplantat,Unite U1160, Paris, France
-
- Russ, Graeme (författare)
- Royal Adelaide Hosp, Cent & Northern Adelaide Renal & Transplantat Ser, Adelaide, SA, Australia;Univ Adelaide, Adelaide, SA, Australia
-
- Rostaing, Lionel (författare)
- Rangueil Univ Hosp Ctr, Dept Nephrol & Organ Transplantat, Toulouse, France;Grenoble Alpes Univ Hosp Ctr, Dept Nephrol Hemodialysis Apheresis & Transplanta, Ave Maquis du Gresivaudan, La Tronche, France
-
visa fler...
-
- Legendre, Christophe (författare)
- Univ Paris 05, Hop Necker Enfants Malad, Sorbonne Paris Cite, Adult Nephrol Transplantat Serv, Paris, France;Hop Necker Enfants Malad, INSERM, Inst Necker Enfants Malad, U1151, Paris, France
-
- Tufveson, Gunnar (författare)
- Uppsala universitet,Transplantationskirurgi
-
- Chadban, Steve (författare)
- Univ Sydney, Royal Prince Alfred Hosp, Dept Renal Med, Sydney, NSW, Australia
-
- Grinyo, Josep (författare)
- Univ Barcelona, Hosp Univ Bellvitge, Dept Nephrol, Barcelona, Spain
-
- Mamode, Nizam (författare)
- Guys & St Thomas Evelina London Childrens & Great, Dept Transplant Surg, London, England
-
- Rigotti, Paolo (författare)
- Univ Hosp Padua, Kidney & Pancreas Transplant Unit, Padua, Italy
-
- Couzi, Lionel (författare)
- Bordeaux Univ, ImmunoConcEpT, UMR CNRS 5164, Bordeaux, France;CHU, Dept Nephrol Transplantat Dialysis Apheresis, Bordeaux, France
-
- Buchler, Matthias (författare)
- Tours Univ Hosp, Dept Nephrol, Tours, France
-
- Sandrini, Silvio (författare)
- Univ Brescia, Div Nephrol, Brescia, Italy;Spedali Civili Gen Hosp, Brescia, Italy
-
- Dain, Bradley (författare)
- Alexion Pharmaceut, Boston, MA USA
-
- Garfield, Mary (författare)
- Alexion Pharmaceut, Boston, MA USA;Arvinas, New Haven, CT USA
-
- Ogawa, Masayo (författare)
- Alexion Pharmaceut, Boston, MA USA
-
- Richard, Tristan (författare)
- Alexion Pharmaceut, Boston, MA USA
-
- Marks, William H. (författare)
- Alexion Pharmaceut, Boston, MA USA
-
visa färre...
-
(creator_code:org_t)
- WILEY, 2019
- 2019
- Engelska.
-
Ingår i: American Journal of Transplantation. - : WILEY. - 1600-6135 .- 1600-6143. ; 19:10, s. 2865-2875
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The presence of preformed donor-specific antibodies in transplant recipients increases the risk of acute antibody-mediated rejection (AMR). Results of an open-label single-arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies are reported. Participants received eculizumab as follows: 1200 mg immediately before reperfusion; 900 mg on posttransplant days 1, 7, 14, 21, and 28; and 1200 mg at weeks 5, 7, and 9. All patients received thymoglobulin induction therapy and standard maintenance immunosuppression including steroids. The primary end point was treatment failure rate, a composite of biopsy-proved grade II/III AMR (Banff 2007 criteria), graft loss, death, or loss to follow-up, within 9 weeks posttransplant. Eighty patients received transplants (48 women); the median age was 52 years (range 24-70 years). Observed treatment failure rate (8.8%) was significantly lower than expected for standard care (40%; P < .001). By 9 weeks, 3 of 80 patients had experienced AMR, and 4 of 80 had experienced graft loss. At 36 months, graft and patient survival rates were 83.4% and 91.5%, respectively. Eculizumab was well tolerated and no new safety concerns were identified. Eculizumab has the potential to provide prophylaxis against injury caused by acute AMR in such patients (EudraCT 2010-019631-35).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- clinical research
- practice
- complement biology
- donors and donation
- deceased
- immunosuppressant-fusion proteins and monoclonal antibodies
- kidney transplantation
- nephrology
- rejection
- antibody-mediated (ABMR)
- sensitization
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Glotz, Denis
-
Russ, Graeme
-
Rostaing, Lionel
-
Legendre, Christ ...
-
Tufveson, Gunnar
-
Chadban, Steve
-
visa fler...
-
Grinyo, Josep
-
Mamode, Nizam
-
Rigotti, Paolo
-
Couzi, Lionel
-
Buchler, Matthia ...
-
Sandrini, Silvio
-
Dain, Bradley
-
Garfield, Mary
-
Ogawa, Masayo
-
Richard, Tristan
-
Marks, William H ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
- Artiklar i publikationen
-
American Journal ...
- Av lärosätet
-
Uppsala universitet